Ten-year survival of children with acute lymphoblastic leukemia: A report from the Children's Oncology Group Journal Article
| Authors: | Trigg, M. E.; Sather, H. N.; Reaman, G. H.; Tubergen, D. G.; Steinherz, P. G.; Gaynon, P. S.; Uckun, F. M.; Hammond, G. D. |
| Article Title: | Ten-year survival of children with acute lymphoblastic leukemia: A report from the Children's Oncology Group |
| Abstract: | The Children's Cancer Group initiated risk-based allocation for childhood acute lymphoblastic leukemia 3 decades ago. Long-term survival data (minimum follow-up >10 years) is now available. About 3711 eligible children were enrolled in risk-adjusted treatment protocols (1983-1989). Ten-year event-free survival (EFS) and overall survival were 62% (standard deviation [SD] = 1%) and 73% (SD = 1%). These data showed a significant improvement (P < 0.0001) compared with the predecessor studies. Since 11% of patients with initial relapses survived without second events, these data predicted a cure rate of 73%. Ten-year EFS and survival were improved significantly for patients with intermediate risk (P < 0.0001), high risk (P < 0.0001) and lymphomatous features (P < 0.0001). Key components of therapies included delayed intensification and substitution of intrathecal chemotherapy for prophylactic/preventive cranial radiation in low- and intermediate-risk patients. This is the largest series of children on concurrent studies who were observed more than 10 years. |
| Keywords: | cancer survival; controlled study; treatment outcome; treatment response; survival rate; major clinical study; overall survival; case-control studies; hydroxyurea; prednisone; clinical feature; clinical trial; doxorubicin; drug dose reduction; monotherapy; combined modality therapy; cytarabine; methotrexate; drug megadose; follow-up studies; cancer prevention; multiple cycle treatment; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; maintenance therapy; risk factors; cyclophosphamide; dexamethasone; vincristine; continuous infusion; risk factor; carmustine; acute lymphoblastic leukemia; childhood cancer; skull irradiation; central nervous system; cranial irradiation; time factors; pediatric; survival time; infant; folinic acid; lymphoma; daunorubicin; remission induction; asparaginase; precursor cell lymphoblastic leukemia-lymphoma; cancer relapse; immunophenotyping; symptomatology; children; drug dose regimen; tioguanine; strategic planning; neuroprotection; mercaptopurine |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 49 |
| Issue: | 6 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2008-06-01 |
| Start Page: | 1142 |
| End Page: | 1154 |
| Language: | English |
| DOI: | 10.1080/10428190802074593 |
| PUBMED: | 18569638 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 9" - "Export Date: 17 November 2011" - "CODEN: LELYE" - "Source: Scopus" |
